All In Biotech

Drug Trial Radar · NCT02584933

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

233

Actual

Start

Dec 11, 2015

Primary completion

Jun 9, 2027

Study completion Jun 9, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.

Conditions

  • ALK Positive Malignancies

Interventions

  • ceritinibDrug

    hard gelatin capsule or hard tablet for oral use up to 750 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Until no patients are left on study up to 5 years

Locations

71 sites in 21 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Loma Linda University

    Loma Linda, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Maryland Oncology Hematology P A

    Rockville, Maryland

  • Essex Oncology of North Jersey PA

    Belleville, New Jersey

  • Novartis Investigative Site

    Auckland, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Montería, Colombia

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Regensburg, Bavaria, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Novara, Italy

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Brescia, BS, Italy

  • Novartis Investigative Site

    Meldola, FC, Italy

  • Novartis Investigative Site

    Monza, MB, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.